Picture of Aequus Pharmaceuticals logo

AQS Aequus Pharmaceuticals Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-3.03%
3m-42.64%
6m-61.4%
1yr-55.65%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-75%
50d MA-47.55%
200d MA-55.42%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-557.95%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Aequus Pharmaceuticals EPS forecast chart

Profile Summary

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
January 3rd, 2013
Public Since
March 17th, 2015
No. of Employees
12
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
132,634,431

AQS Share Price Performance

Upcoming Events for AQS

Q4 2023 Aequus Pharmaceuticals Inc Earnings Release

Q1 2024 Aequus Pharmaceuticals Inc Earnings Release

Aequus Pharmaceuticals Inc Annual Shareholders Meeting

Q2 2024 Aequus Pharmaceuticals Inc Earnings Release

Similar to AQS

Picture of Avricore Health logo

Avricore Health

ca flag iconTSX Venture Exchange

Picture of Biosyent logo

Biosyent

ca flag iconTSX Venture Exchange

Picture of Cytophage Technologies logo

Cytophage Technologies

ca flag iconTSX Venture Exchange

Picture of Decibel Cannabis logo

Decibel Cannabis

ca flag iconTSX Venture Exchange

Picture of Delivra Health Brands logo

Delivra Health Brands

ca flag iconTSX Venture Exchange

FAQ